Home / Health / Pharma Giants Fined for Obesity Drug Ads
Pharma Giants Fined for Obesity Drug Ads
4 May
Summary
- France's medicine safety agency imposed fines on two major pharmaceutical firms.
- Novo Nordisk and Eli Lilly were penalized for their advertising campaigns.
- Fines were issued over promotions for obesity treatment drugs.
France's national medicine safety agency, ANSM, announced significant fines on May 4th, 2026, targeting pharmaceutical companies Novo Nordisk and Eli Lilly. These penalties are a direct result of their advertising strategies concerning obesity treatments.
Novo Nordisk France was particularly impacted, facing a fine of €1.78 million. A substantial part of this penalty is attributed to advertisements promoting their drug Saxenda. Eli Lilly also received fines, though specific amounts were not detailed in the initial report.
The agency's action underscores a stringent regulatory environment for the marketing of weight-loss medications. This move reflects a broader concern over the promotion and accessibility of such drugs within France.
